CDKN1B Gene Multiple Endocrine Neoplasia Type 4 Genetic Test
Test Name: CDKN1B Gene Multiple Endocrine Neoplasia Type 4 Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Cancer
Doctor: Oncologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for CDKN1B Gene Multiple Endocrine Neoplasia Type 4 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CDKN1B Gene Multiple Endocrine Neoplasia Type 4 NGS Genetic DNA Test gene CDKN1B
Test Details: The CDKN1B gene is associated with multiple endocrine neoplasia type 4 (MEN4), which is a rare genetic disorder characterized by the development of tumors in multiple endocrine glands. The CDKN1B gene provides instructions for producing a protein called p27, which plays a role in controlling cell division and preventing the formation of tumors. NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously, providing a comprehensive assessment of an individual’s genetic makeup. In the context of MEN4, NGS genetic testing can identify mutations or variations in the CDKN1B gene that may be associated with the development of the disorder. NGS genetic testing for MEN4 can be useful in diagnosing individuals with suspected MEN4, as well as in identifying carriers of CDKN1B gene mutations within families. This information can help guide medical management and surveillance for individuals at risk of developing MEN4-related tumors. It is important to note that NGS genetic testing is typically performed by healthcare professionals with expertise in genetics, and the results should be interpreted in the context of the individual’s medical history and family history. Genetic counseling is often recommended before and after genetic testing to discuss the potential implications of the results and to provide support and guidance.
| Test Name | CDKN1B Gene Multiple endocrine neoplasia type 4 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for CDKN1B Gene Multiple endocrine neoplasia type 4 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CDKN1B Gene Multiple endocrine neoplasia type 4 NGS Genetic DNA Test gene CDKN1B |
| Test Details | The CDKN1B gene is associated with multiple endocrine neoplasia type 4 (MEN4), which is a rare genetic disorder characterized by the development of tumors in multiple endocrine glands. The CDKN1B gene provides instructions for producing a protein called p27, which plays a role in controlling cell division and preventing the formation of tumors. NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously, providing a comprehensive assessment of an individual’s genetic makeup. In the context of MEN4, NGS genetic testing can identify mutations or variations in the CDKN1B gene that may be associated with the development of the disorder. NGS genetic testing for MEN4 can be useful in diagnosing individuals with suspected MEN4, as well as in identifying carriers of CDKN1B gene mutations within families. This information can help guide medical management and surveillance for individuals at risk of developing MEN4-related tumors. It is important to note that NGS genetic testing is typically performed by healthcare professionals with expertise in genetics, and the results should be interpreted in the context of the individual’s medical history and family history. Genetic counseling is often recommended before and after genetic testing to discuss the potential implications of the results and to provide support and guidance. |
